Williams T M, Ciccarone T M, MacTough S C, Rooney C S, Balani S K, Condra J H, Emini E A, Goldman M E, Greenlee W J, Kauffman L R
Department of Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486-0004.
J Med Chem. 1993 Apr 30;36(9):1291-4. doi: 10.1021/jm00061a022.
A series of highly potent, structurally novel, non-nucleoside RT inhibitors has been described. Low nanomolar concentrations of 5-chloro-3-(phenylsulfonyl)-indole-2-carboxamide (1) inhibit the HIV-1 RT enzyme in vitro and HTLVIIIb viral spread in MT-4 human T-lymphoid cells. Good oral bioavailability was observed in rhesus monkeys upon oral dosing of 1 as a suspension in methocel. When compared to other non-nucleoside inhibitors (e.g. 15-18), 1 possesses improved inhibitory potency with respect to the wild-type RT, as well as the K103N and Y181C mutant enzymes. Additional studies within this class of inhibitors are in progress.